Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Natco Pharma has received a demand notice dated 12th May 2026 from the National Pharmaceutical Pricing Authority (NPPA). The notice directs the company to deposit ₹4,92,25,923 (approximately ₹4.92 crore), which includes the overcharge amount, penalty, and interest. The NPPA alleges that the company overcharged for 2 drugs during the period April 2023 to November 2023, in violation of the Drugs Price Control Order, 2013. The company has clarified that there is no material impact on its financial, operational, or other activities as a result of this demand.
While the demand amount of around ₹4.92 crore is material in absolute terms, the company has stated there is no material operational or financial impact. The stock may see minor negative sentiment due to the regulatory notice, but the company's dismissal of material impact should limit downside pressure.